{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T12:33:21Z","timestamp":1760099601847},"reference-count":20,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2004,10,22]],"date-time":"2004-10-22T00:00:00Z","timestamp":1098403200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transfusion"],"published-print":{"date-parts":[[2004,11]]},"abstract":"<jats:p><jats:bold>BACKGROUND:\u2002<\/jats:bold> Recombinant activated factor VII (rFVIIa) is being tested to improve hemostasis in a variety of bleeding disorders. Clinical indications and efficacy are still being evaluated for this product.<\/jats:p><jats:p><jats:bold>CASE REPORT:\u2002<\/jats:bold> Over a 17\u2010month period, rFVIIa was used to treat central nervous system hemorrhage in three patients who were found to have isolated FVII deficiency (21%, 40%, 27%). Patient A fell 30 feet, Patient B suffered a motor vehicle accident, and Patient C had a spinal cord hematoma. None of the patients had a history of bleeding diathesis. All three patients received rFVIIa after failing initial treatment with fresh\u2010frozen plasma.<\/jats:p><jats:p><jats:bold>RESULTS:\u2002<\/jats:bold> Patient A was treated with 11 doses (initial dose 95 \u00b5g\/kg; subsequent doses 8\u201038 \u00b5g\/kg) over 10 days; Patient B received 13 doses (45\u201060 \u00b5g\/kg) over 13 days; and Patient C received 5 doses (12\u201024 \u00b5g\/kg) over 4 days. The prothrombin time corrected from 16.2 \u00b1 1.8 (mean \u00b1 SD) to 11.2 \u00b1 1.6 seconds after infusion of rFVIIa, but returned to pretreatment level in 14 \u00b1 4 hours. At the cessation of therapy, all patients showed neurologic improvement. No complications related to the infusion of rFVIIa occurred.<\/jats:p><jats:p><jats:bold>CONCLUSION: \u2002<\/jats:bold> The use of rFVIIa may be of value both for its general effect on hemostasis, and specifically in the setting where there is a documented reduction in FVII. Doses lower than those used in patients with FVIII inhibitors appear to be effective in the setting of central nervous sytem hemorrhage.<\/jats:p>","DOI":"10.1111\/j.1537-2995.2004.04080.x","type":"journal-article","created":{"date-parts":[[2004,10,22]],"date-time":"2004-10-22T17:34:51Z","timestamp":1098466491000},"page":"1562-1566","source":"Crossref","is-referenced-by-count":23,"title":["The use of recombinant activated factor VII in three patients with central nervous system hemorrhages associated with factor VII deficiency"],"prefix":"10.1111","volume":"44","author":[{"given":"Weei\u2010Yuarn","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margot S.","family":"Kruskall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth A.","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynne","family":"Uhl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beth H.","family":"Shaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2004,10,22]]},"reference":[{"key":"e_1_2_5_2_2","unstructured":"Molecular basis of blood coagulation.In: Hoffman R Benz EJ Shattil SJ et al eds. Hematology basic principles and practice 2nd ed. New York:Churchill Livingstone 1995:1566\u201087."},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V66.6.1284.1284"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1615357"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2002.00017.x"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1423-0410.1999.7730131.x"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)05155-7"},{"issue":"1","key":"e_1_2_5_8_2","first-page":"159","article-title":"Clinical experience with recombinant factor VIIa in patients with thrombocytopenia","volume":"26","author":"Kristensen J","year":"1996","journal-title":"Haemostasis"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V94.11.3951"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2000-8459"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005373-200109000-00002"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0952-8180(03)00034-5"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.3171\/jns.2003.98.3.0611"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03545.x"},{"key":"e_1_2_5_15_2","first-page":"8:CS98","article-title":"Recombinant coagulation factor VIIa for rapid preoperative correction of warfarin\u2010related coagulopathy in patients with acute subdural hematoma","author":"Veshchev I","year":"2002","journal-title":"Med Sci Monit"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.3171\/jns.2003.98.4.0737"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2000.00345.x"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008506-200310000-00008"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1613879"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1227\/01.NEU.0000068830.54968.A8"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1023777031589"}],"container-title":["Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1537-2995.2004.04080.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1537-2995.2004.04080.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1537-2995.2004.04080.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T12:12:01Z","timestamp":1697285521000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1537-2995.2004.04080.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,10,22]]},"references-count":20,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2004,11]]}},"alternative-id":["10.1111\/j.1537-2995.2004.04080.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1537-2995.2004.04080.x","archive":["Portico"],"relation":{},"ISSN":["0041-1132","1537-2995"],"issn-type":[{"value":"0041-1132","type":"print"},{"value":"1537-2995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,10,22]]}}}